Investor Alert

New York Markets Close in:

Market Pulse Archives

May 3, 2021, 10:52 a.m. EDT

Ocugen's stock is up after sharing preprint about COVID-19 vaccine effectiveness against lesser known Brazilian variant

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Ocugen Inc. (OCGN)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Ocugen Inc. /zigman2/quotes/208160861/composite OCGN +0.27% were up 20.2% in trading on Monday after the Pennslyvania company said a COVID-19 vaccine it is contracted to develop with Indian biotechnology firm Bharat Biotech International Ltd. is "potentially" effective against B., or P.2., a variant first identified in Brazil in April 2020. The variant has been designated a variant of interest in the U.S. but is not considered a more serious variant of concern like the B.1.1.7. out of the U.K. or the P.1, which was also first identified in Brazil, according to the Centers for Disease Control and Prevention . The study cited by Ocugen is a preprint, which is preliminary medical research that has not been peer-reviewed, and it compared IgG antibody titers in people who had received the shots to those who have recovered from COVID-19. The study was conducted in a lab and included 61 sera samples, two of which had the B. variant. Ocugen has said it is developing Bharat's vaccine, which was approved in India in January, for the U.S. but has not yet initiated clinical trials for this market. Ocugen's stock has soared 729.8% since the start of the year, while the S&P 500 /zigman2/quotes/210599714/realtime SPX +1.38% is up 11.3%.

US : U.S.: Nasdaq
$ 3.74
+0.0100 +0.27%
Volume: 5.94M
Jan. 20, 2022 11:38a
P/E Ratio
Dividend Yield
Market Cap
$742.96 million
Rev. per Employee
+62.72 +1.38%
Volume: 849.16M
Jan. 20, 2022 11:38a

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.